Main Therapeutic Uses of Epiletam

Epiletam contains the active substance levetiracetam, an antiepileptic medication used to treat various types of seizures in patients with epilepsy. It works by stabilizing electrical activity in the brain to prevent the occurrence of abnormal discharges that lead to seizures.

Treatment of Monotherapy Seizures

Epiletam is used as a standalone treatment (monotherapy) for a specific type of seizure in adults and adolescents from 16 years of age who have been newly diagnosed with epilepsy:

• Partial-onset seizures with or without secondary generalization: These are seizures that initially affect only one part of the brain but may subsequently spread to both sides.

Adjunctive Therapy

Epiletam is also used as an add-on (adjunctive) therapy alongside other antiepileptic medications to treat the following conditions:

• Partial-onset seizures with or without generalization: For use in adults, adolescents, children, and infants from 1 month of age.
• Myoclonic seizures: Specifically for patients from 12 years of age with Juvenile Myoclonic Epilepsy. These seizures involve brief, shock-like jerks of a muscle or group of muscles.
• Primary generalized tonic-clonic seizures: For adults and adolescents from 12 years of age with Idiopathic Generalized Epilepsy. These are major seizures that involve loss of consciousness and rhythmic body shaking.

Benefits and Goals of Treatment

The primary objective of treatment with Epiletam is to improve the patient's quality of life by managing the frequency and intensity of epileptic events. The clinical benefits include:

• Seizure Reduction: Significant decrease in the number of seizure episodes experienced by the patient.
• Seizure Control: For some patients, the medication can lead to complete freedom from seizures over an extended period.
• Broad Spectrum of Activity: Effectiveness across different age groups and various seizure types, ranging from focal (partial) to generalized epilepsy syndromes.

Regulatory References

1. European Medicines Agency summary

Who can and cannot use Epiletam?

The eligibility for Epiletam (levetiracetam) is defined strictly by official government regulatory documents based on age, therapy type, and specific physiological conditions.

Absolute Contraindications

Epiletam is formally contraindicated (must not be used) in patients with a known hypersensitivity to the active substance, levetiracetam, or to other pyrrolidone derivatives, as stated in the regulatory labeling.

Age-Related Eligibility Status

Eligibility depends on the type of seizure being addressed and the treatment approach, with approved minimum ages varying across indications:

Safety and effectiveness of the medicine as monotherapy in patients younger than 16 years have not been established in official labeling.

Conditional Use and Restrictions

Use is permitted but restricted for patients with impaired organ function, as levetiracetam is primarily cleared by the kidneys. Mandatory adjustment is required for all degrees of renal impairment, including patients on dialysis. For patients with severe hepatic impairment, official guidance recommends prior assessment of renal function, as it may affect the necessary starting regimen. For pregnancy and lactation, use is permitted only if clinically needed after careful assessment, due to its excretion into breast milk and observed pharmacokinetic changes during pregnancy.

Interactions with other medicines and products

The interaction profile of Epiletam (Levetiracetam) is primarily defined by its low potential for metabolic drug-drug interactions and its high dependence on renal clearance.

Documented Pharmacokinetic and Clearance Patterns

Levetiracetam's major metabolic pathway is not dependent on liver Cytochrome P450 isoenzymes and the drug is less than 10% bound to plasma proteins. This indicates a low likelihood of clinically significant interactions via these common routes, a finding supported by official regulatory documentation. Co-administration with enzyme-inducing Antiepileptic Drugs (AEDs), such as Carbamazepine, is officially documented to increase Levetiracetam's apparent clearance, resulting in reduced drug exposure.

Pharmacodynamic and Substance Interactions

Co-administration with Central Nervous System (CNS) Depressants or alcohol may lead to additive pharmacodynamic effects, specifically increasing the risk of somnolence and drowsiness. There are no known restrictions for administration relative to general meals; the drug may be taken with or without food. No drug-drug combination is formally classified as a contraindication in regulatory labeling; contraindication is reserved only for known hypersensitivity.

Population-Specific Interaction Notes

Due to the drug's primary reliance on renal elimination, clearance is reduced in patients with impaired renal function. Regulatory documents recommend the assessment of renal function prior to dose selection for patients with severe hepatic impairment, linking hepatic status to this renal-dependent clearance interaction.

Modulating Presynaptic Communication via SV2A

Levetiracetam acts by binding specifically to the Synaptic Vesicle Protein 2A ( SV2A), a protein located on the membrane of synaptic vesicles in the presynaptic nerve terminal. By modulating SV2A function, the molecule limits the Ca^2+-dependent over-release of chemical signals, such as excitatory glutamate. This mechanistic action results in the restriction of excessive chemical communication between nerve cells.

Dampening Neuronal Hyperexcitability

The primary physiological consequence of SV2A modulation is the selective reduction of widespread neuronal hypersynchronization and epileptiform burst firing. This action modulates the nerve network's response to pathological overactivity, supporting more controlled electrical activity in the central nervous system by maintaining functional neurotransmission at baseline levels.

The use of Epiletam (Levetiracetam) is based on established administration protocols. The medicine is supplied for both oral intake (film-coated tablets, oral solution) and for intravenous (IV) infusion. Conversion between these two routes maintains the same total daily dose, with IV use typically being temporary and limited to four days.

For adults, the standard regimen starts at 1000 mg per day, administered in two equally divided doses (twice daily). The dose is typically adjusted every two weeks in 1000 mg increments, with the maximum dose reaching 3000 mg per day. Oral forms may be taken with or without food.

Proper administration requires adherence to specific procedures. Oral tablets must be swallowed whole. The IV concentrate must first be diluted in at least 100 mL of a compatible liquid and administered over a 15-minute infusion period.

Dosing modifications are applied for specific patient populations. A reduced daily dose is required for patients with renal impairment due to the medicine's clearance profile, and pediatric dosing is calculated based on body weight. Discontinuation of Epiletam must follow a gradual tapering protocol over several weeks to maintain procedural consistency.

Research Evidence / Overview of Studies

This section summarizes the published research that has examined Epiletam (levetiracetam). It is intended only to describe the available evidence and does not constitute medical advice, treatment suitability, or a recommendation for use.

Research on Proposed Mechanism

Research investigated the proposed mechanism by which Epiletam interacts with cellular pathways, primarily focusing on its intended effects within the central nervous system. Studies were conducted in laboratory and pre-clinical settings to evaluate the drug's interaction with specific signaling molecules, particularly the synaptic vesicle glycoprotein 2 A (SV2 A).

Phase III Clinical Trials for Long-Term Management

The majority of clinical data for Epiletam comes from large, multi-center Phase III randomized controlled trials (RCTs). The drug has been studied in research settings as adjunctive or monotherapy for the long-term management of certain seizure disorders, including partial-onset and generalized seizures.

• Primary Objective: Studies have explored whether it may affect the frequency and severity of seizures and disease activity over periods up to two years.
• Secondary Objectives: Secondary research goals included assessing long-term safety and tolerability. The study protocols included requirements for participant monitoring and specified instructions for drug management during the trial.

Key Findings from RCTs

The studies reported findings on the drug’s effects, with data suggesting that seizure frequency outcomes were affected. These RCTs were instrumental in documenting the long-term safety profile of the drug, with findings on tolerability noted. A discussion of the evidence summary and individual health circumstances with a qualified healthcare professional is recommended.

Key Studies & References

1. Levetiracetam in the treatment of primary generalized tonic-clonic seizures: an adjunctive, double-blind, randomized, placebo-controlled trial
2. NICE Guideline: Epilepsies: diagnosis and management (CG137)

Storage Conditions

Epiletam (levetiracetam) tablets and oral solution must be stored at Controlled Room Temperature (20 C to 25 C), with permitted temperature excursions between 15 C and 30 C. The medicine must be kept in its original container and protected from moisture.

• Oral Solution Stability: Once opened, the Epiletam oral solution is stable for and must be discarded 4 months after first opening the bottle.
• Child Protection: The product must be stored out of the sight and reach of children.

Disposal Requirements

Unused or expired Epiletam should be disposed of through an authorized drug take-back program. If a program is unavailable, follow the household disposal guidelines: remove the medicine from its original container, mix it with an undesirable substance like dirt or used coffee grounds, and place the mixture in a sealed container before disposal in household trash. The medication should not be flushed down a toilet or poured into a sink.